Table 1. Demographic and clinical characteristics of the samples from individual ISPC member sites included in the genetic analysis.
| Characteristic | Study 1a | Study 2a | Study 4a | Study 5a | Study 6a | Study 7a | Study 8a | Total/average |
|---|---|---|---|---|---|---|---|---|
| Country | Taiwan | Taiwan | Germany | Germany | USA | Thailand | Japan | — |
| Number of subjects in GWAS | 177 | 245 | 50 | 58 | 190 | 24 | 121 | 865 |
| Age, mean (s.d.) | 47.1 (15.2) | 41.4 (13.7) | 50.1 (17.1) | 46.3 (13.6) | 39.4 (13.6) | 44.6 (10.7) | 46.2 (15.4) | 43.7 (14.7) |
| Sex, N (%) female | 97 (54.8%) | 201 (82.0%) | 32 (64.0%) | 43 (74.1%) | 116 (61.1%) | 15 (62.5%) | 57 (47.1%) | 561 (64.9%) |
| Baseline HRSD-17 score, mean (s.d.) | 26.4 (4.05) | 21.3 (4.18) | 22.6 (7.55) | 24.2 (6.10) | 21.0 (4.87) | 15.0 (3.58) | 20.0 (5.68) | 22.2 (5.53) |
| 4-Week HRSD-17 score, mean (s.d.) | 13.6 (5.33) | 12.4 (5.17) | 8.84 (7.90) | 13.6 (7.81) | 12.0 (6.05) | 7.58 (6.79) | 9.37 (5.73) | 11.9 (6.12) |
| Remitters at 4 weeks, N (%) | 20 (11.3%) | 47 (19.2%) | 26 (52.0%) | 17 (29.3%) | 49 (25.8%) | 16 (66.7%) | 51 (42.1%) | 226 (26.1%) |
| Responders at 4 weeks, N (%) | 89 (50.3%) | 97 (39.6%) | 34 (68.0%) | 24 (41.4%) | 82 (43.2%) | 15 (62.5%) | 75 (62.0%) | 416 (48.1%) |
Abbreviations: GWAS, genome-wide association study; HRSD, Hamilton Rating Scale for Depression; ISPC, International SSRI Pharmacogenomics Consortium.
a
Study numbers correspond to the contributing studies described in Supplementary Table S1.